Which has stronger valuation and earnings, LXEO or MLTX?

MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lexeo Therapeutics N/A N/A -$99.96M -$1.45 N/A MoonLake Immunotherapeutics N/A N/A -$227.32M -$3.87 N/A

Is LXEO or MLTX more profitable?

Lexeo Therapeutics' return on equity of -47.48% beat MoonLake Immunotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Lexeo Therapeutics N/A -47.48% -41.72% MoonLake Immunotherapeutics N/A -85.15% -60.52%

Does the media refer more to LXEO or MLTX?

In the previous week, MoonLake Immunotherapeutics had 12 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 15 mentions for MoonLake Immunotherapeutics and 3 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 0.70 beat MoonLake Immunotherapeutics' score of 0.57 indicating that Lexeo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexeo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MoonLake Immunotherapeutics 4 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer HROW or LXEO?

In the previous week, Harrow and Harrow both had 3 articles in the media. Harrow's average media sentiment score of 0.72 beat Lexeo Therapeutics' score of 0.70 indicating that Harrow is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Harrow 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lexeo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to LXEO or ARDX?

In the previous week, Ardelyx had 1 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 4 mentions for Ardelyx and 3 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 0.70 beat Ardelyx's score of 0.62 indicating that Lexeo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexeo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ardelyx 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, GHRS or LXEO?

GH Research is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GH Research N/A N/A -$48.26M -$0.92 N/A Lexeo Therapeutics N/A N/A -$99.96M -$1.45 N/A

Is GHRS or LXEO more profitable?

GH Research's return on equity of -19.36% beat Lexeo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets GH Research N/A -19.36% -18.73% Lexeo Therapeutics N/A -47.48% -41.72%

Does the media prefer GHRS or LXEO?

In the previous week, GH Research had 1 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 4 mentions for GH Research and 3 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 0.70 beat GH Research's score of 0.47 indicating that Lexeo Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GH Research 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lexeo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ATAI or LXEO?

In the previous week, Atai Beckley had 2 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 5 mentions for Atai Beckley and 3 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 0.70 beat Atai Beckley's score of 0.63 indicating that Lexeo Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atai Beckley 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lexeo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Lexeo Therapeutics (LXEO) Competitors

$4.81 +0.06 (+1.26%)

Closing price 04:00 PM Eastern

Extended Trading

$4.81 0.00 (0.00%)

As of 07:58 PM Eastern

Compare

LXEO vs. MLTX, HROW, ARDX, GHRS, and ATAI

Should you buy Lexeo Therapeutics stock or one of its competitors? MarketBeat compares Lexeo Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lexeo Therapeutics include MoonLake Immunotherapeutics (MLTX), Harrow (HROW), Ardelyx (ARDX), GH Research (GHRS), and Atai Beckley (ATAI). These companies are all part of the "pharmaceutical products" industry.

How does Lexeo Therapeutics compare to MoonLake Immunotherapeutics?

Lexeo Therapeutics (NASDAQ:LXEO) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, dividends, valuation and institutional ownership.

Lexeo Therapeutics currently has a consensus target price of $18.75, indicating a potential upside of 289.81%. MoonLake Immunotherapeutics has a consensus target price of $23.85, indicating a potential upside of 19.77%. Given Lexeo Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Lexeo Therapeutics is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.38

60.7% of Lexeo Therapeutics shares are owned by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. 2.0% of Lexeo Therapeutics shares are owned by insiders. Comparatively, 12.1% of MoonLake Immunotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Lexeo Therapeutics' return on equity of -47.48% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexeo Therapeutics	N/A	-47.48%	-41.72%
MoonLake Immunotherapeutics	N/A	-85.15%	-60.52%

Lexeo Therapeutics has a beta of 1.39, indicating that its share price is 39% more volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market.

MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.45	N/A
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.87	N/A

In the previous week, MoonLake Immunotherapeutics had 12 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 15 mentions for MoonLake Immunotherapeutics and 3 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 0.70 beat MoonLake Immunotherapeutics' score of 0.57 indicating that Lexeo Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexeo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MoonLake Immunotherapeutics	4 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Lexeo Therapeutics beats MoonLake Immunotherapeutics on 10 of the 14 factors compared between the two stocks.

How does Lexeo Therapeutics compare to Harrow?

Harrow (NASDAQ:HROW) and Lexeo Therapeutics (NASDAQ:LXEO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

Harrow has higher revenue and earnings than Lexeo Therapeutics. Harrow is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Harrow	$272.30M	5.63	-$5.14M	-$0.41	N/A
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.45	N/A

72.8% of Harrow shares are owned by institutional investors. Comparatively, 60.7% of Lexeo Therapeutics shares are owned by institutional investors. 12.8% of Harrow shares are owned by company insiders. Comparatively, 2.0% of Lexeo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Harrow and Harrow both had 3 articles in the media. Harrow's average media sentiment score of 0.72 beat Lexeo Therapeutics' score of 0.70 indicating that Harrow is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Harrow	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lexeo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lexeo Therapeutics has a net margin of 0.00% compared to Harrow's net margin of -5.57%. Harrow's return on equity of 19.59% beat Lexeo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Harrow	-5.57%	19.59%	2.26%
Lexeo Therapeutics	N/A	-47.48%	-41.72%

Harrow currently has a consensus target price of $69.43, indicating a potential upside of 68.72%. Lexeo Therapeutics has a consensus target price of $18.75, indicating a potential upside of 289.81%. Given Lexeo Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Lexeo Therapeutics is more favorable than Harrow.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Harrow	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Harrow has a beta of 0.28, indicating that its share price is 72% less volatile than the broader market. Comparatively, Lexeo Therapeutics has a beta of 1.39, indicating that its share price is 39% more volatile than the broader market.

Summary

Harrow beats Lexeo Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Lexeo Therapeutics compare to Ardelyx?

Lexeo Therapeutics (NASDAQ:LXEO) and Ardelyx (NASDAQ:ARDX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, profitability, valuation, risk, institutional ownership and dividends.

Lexeo Therapeutics currently has a consensus price target of $18.75, suggesting a potential upside of 289.81%. Ardelyx has a consensus price target of $15.73, suggesting a potential upside of 200.71%. Given Lexeo Therapeutics' higher possible upside, equities analysts clearly believe Lexeo Therapeutics is more favorable than Ardelyx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Ardelyx	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.91

Ardelyx has higher revenue and earnings than Lexeo Therapeutics. Ardelyx is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.45	N/A
Ardelyx	$407.32M	3.17	-$61.60M	-$0.23	N/A

In the previous week, Ardelyx had 1 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 4 mentions for Ardelyx and 3 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 0.70 beat Ardelyx's score of 0.62 indicating that Lexeo Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexeo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ardelyx	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

60.7% of Lexeo Therapeutics shares are owned by institutional investors. Comparatively, 58.9% of Ardelyx shares are owned by institutional investors. 2.0% of Lexeo Therapeutics shares are owned by company insiders. Comparatively, 5.3% of Ardelyx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Lexeo Therapeutics has a beta of 1.39, meaning that its share price is 39% more volatile than the broader market. Comparatively, Ardelyx has a beta of 0.58, meaning that its share price is 42% less volatile than the broader market.

Lexeo Therapeutics has a net margin of 0.00% compared to Ardelyx's net margin of -13.58%. Ardelyx's return on equity of -38.11% beat Lexeo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexeo Therapeutics	N/A	-47.48%	-41.72%
Ardelyx	-13.58%	-38.11%	-11.85%

Summary

Ardelyx beats Lexeo Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Lexeo Therapeutics compare to GH Research?

GH Research (NASDAQ:GHRS) and Lexeo Therapeutics (NASDAQ:LXEO) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, media sentiment, valuation, dividends, profitability, risk and analyst recommendations.

In the previous week, GH Research had 1 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 4 mentions for GH Research and 3 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 0.70 beat GH Research's score of 0.47 indicating that Lexeo Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GH Research	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lexeo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

56.9% of GH Research shares are owned by institutional investors. Comparatively, 60.7% of Lexeo Therapeutics shares are owned by institutional investors. 2.0% of Lexeo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

GH Research is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GH Research	N/A	N/A	-$48.26M	-$0.92	N/A
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.45	N/A

GH Research has a beta of 1.31, suggesting that its stock price is 31% more volatile than the broader market. Comparatively, Lexeo Therapeutics has a beta of 1.39, suggesting that its stock price is 39% more volatile than the broader market.

GH Research presently has a consensus target price of $40.38, indicating a potential upside of 41.72%. Lexeo Therapeutics has a consensus target price of $18.75, indicating a potential upside of 289.81%. Given Lexeo Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Lexeo Therapeutics is more favorable than GH Research.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GH Research	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

GH Research's return on equity of -19.36% beat Lexeo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GH Research	N/A	-19.36%	-18.73%
Lexeo Therapeutics	N/A	-47.48%	-41.72%

Summary

Lexeo Therapeutics beats GH Research on 8 of the 14 factors compared between the two stocks.

How does Lexeo Therapeutics compare to Atai Beckley?

Atai Beckley (NASDAQ:ATAI) and Lexeo Therapeutics (NASDAQ:LXEO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends.

Lexeo Therapeutics has lower revenue, but higher earnings than Atai Beckley. Lexeo Therapeutics is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atai Beckley	$4.09M	482.49	-$660.05M	-$2.23	N/A
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.45	N/A

28.4% of Atai Beckley shares are owned by institutional investors. Comparatively, 60.7% of Lexeo Therapeutics shares are owned by institutional investors. 26.8% of Atai Beckley shares are owned by insiders. Comparatively, 2.0% of Lexeo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Lexeo Therapeutics has a net margin of 0.00% compared to Atai Beckley's net margin of -19,019.44%. Lexeo Therapeutics' return on equity of -47.48% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atai Beckley	-19,019.44%	-89.79%	-63.58%
Lexeo Therapeutics	N/A	-47.48%	-41.72%

Atai Beckley has a beta of 1.6, suggesting that its stock price is 60% more volatile than the broader market. Comparatively, Lexeo Therapeutics has a beta of 1.39, suggesting that its stock price is 39% more volatile than the broader market.

Atai Beckley currently has a consensus price target of $16.00, indicating a potential upside of 198.51%. Lexeo Therapeutics has a consensus price target of $18.75, indicating a potential upside of 289.81%. Given Lexeo Therapeutics' higher probable upside, analysts plainly believe Lexeo Therapeutics is more favorable than Atai Beckley.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atai Beckley	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

In the previous week, Atai Beckley had 2 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 5 mentions for Atai Beckley and 3 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 0.70 beat Atai Beckley's score of 0.63 indicating that Lexeo Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atai Beckley	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lexeo Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Lexeo Therapeutics beats Atai Beckley on 8 of the 15 factors compared between the two stocks.

Get Lexeo Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LXEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LXEO vs. The Competition

Export

Metric	Lexeo Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$372.98M	$3.04B	$6.85B	$12.20B
Dividend Yield	N/A	1.87%	2.66%	6.22%
P/E Ratio	-3.32	19.67	26.04	24.36
Price / Sales	N/A	349.52	550.17	103.06
Price / Cash	N/A	56.85	29.09	36.93
Price / Book	1.42	4.25	10.98	6.49
Net Income	-$99.96M	$64.45M	$3.57B	$336.61M
7 Day Performance	-4.56%	4.17%	3.06%	0.90%
1 Month Performance	-6.42%	1.44%	0.72%	-0.36%
1 Year Performance	16.75%	34.07%	36.82%	31.26%

Lexeo Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LXEO Lexeo Therapeutics	2.0882 of 5 stars	$4.81 +1.3%	$18.75 +289.8%	+15.3%	$372.98M	N/A	N/A	58
MLTX MoonLake Immunotherapeutics	2.716 of 5 stars	$21.76 -1.8%	$23.85 +9.6%	-58.1%	$1.60B	N/A	N/A	2	Gap Down
HROW Harrow	4.2565 of 5 stars	$42.66 +0.6%	$69.43 +62.8%	+36.2%	$1.59B	$272.30M	N/A	180
ARDX Ardelyx	2.5925 of 5 stars	$6.31 -1.0%	$15.73 +149.4%	+50.0%	$1.56B	$427.68M	N/A	90
GHRS GH Research	3.4597 of 5 stars	$22.78 +3.1%	$40.38 +77.3%	+126.8%	$1.56B	N/A	N/A	10	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LXEO) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lexeo Therapeutics (LXEO) Competitors

LXEO vs. MLTX, HROW, ARDX, GHRS, and ATAI

How does Lexeo Therapeutics compare to MoonLake Immunotherapeutics?

Summary

How does Lexeo Therapeutics compare to Harrow?

Summary

How does Lexeo Therapeutics compare to Ardelyx?

Summary

How does Lexeo Therapeutics compare to GH Research?

Summary

How does Lexeo Therapeutics compare to Atai Beckley?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXEO vs. The Competition

Lexeo Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lexeo Therapeutics (LXEO) Competitors

LXEO vs. MLTX, HROW, ARDX, GHRS, and ATAI

How does Lexeo Therapeutics compare to MoonLake Immunotherapeutics?

Do analysts prefer LXEO or MLTX?

Do insiders and institutionals have more ownership in LXEO or MLTX?

Is LXEO or MLTX more profitable?

Which has more volatility and risk, LXEO or MLTX?

Which has stronger valuation and earnings, LXEO or MLTX?

Does the media refer more to LXEO or MLTX?

Summary

How does Lexeo Therapeutics compare to Harrow?

Which has better earnings & valuation, HROW or LXEO?

Do insiders & institutionals have more ownership in HROW or LXEO?

Does the media prefer HROW or LXEO?

Is HROW or LXEO more profitable?

Do analysts prefer HROW or LXEO?

Which has more volatility & risk, HROW or LXEO?

Summary

How does Lexeo Therapeutics compare to Ardelyx?

Do analysts prefer LXEO or ARDX?

Which has stronger earnings and valuation, LXEO or ARDX?

Does the media refer more to LXEO or ARDX?

Do institutionals and insiders hold more shares of LXEO or ARDX?

Which has more risk and volatility, LXEO or ARDX?

Is LXEO or ARDX more profitable?

Summary

How does Lexeo Therapeutics compare to GH Research?

Does the media prefer GHRS or LXEO?

Do institutionals and insiders have more ownership in GHRS or LXEO?

Which has preferable valuation & earnings, GHRS or LXEO?

Which has more volatility and risk, GHRS or LXEO?

Do analysts recommend GHRS or LXEO?

Is GHRS or LXEO more profitable?

Summary

How does Lexeo Therapeutics compare to Atai Beckley?

Which has better earnings and valuation, ATAI or LXEO?

Do insiders and institutionals have more ownership in ATAI or LXEO?

Is ATAI or LXEO more profitable?

Which has more risk & volatility, ATAI or LXEO?

Do analysts recommend ATAI or LXEO?

Does the media prefer ATAI or LXEO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXEO vs. The Competition

Lexeo Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools